1-3 of 3
Ye Yuan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina

Clinical Trials & Observations
Jianxiang Wang, Zhi-Xiang Shen, Giuseppe Saglio, Jie Jin, He Huang, Yu Hu, Xin Du, Jianyong Li, Fanyi Meng, Huanling Zhu, Jianda Hu, Jianmin Wang, Ming Hou, Sabine Hertle, Hans D. Menssen, Christine-Elke Ortmann, Catherine Tribouley, Ye Yuan, Michele Baccarani, Xiaojun Huang
Journal: Blood
Blood (2015) 125 (18): 2771–2778.
https://doi.org/10.1182/blood-2014-09-601674
Published: 2015
Journal Articles

Frontline Nilotinib Results In Superior Rates Of Molecular Response Versus Imatinib In Chinese Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTchina 12-Month Primary Analysis

Xiaojun Huang, Jianxiang Wang, MD, Michele Baccarani, MD, Svetlana Jevtic, Christine-Elke Ortmann, Ye Yuan, Hans D. Menssen, MD, PhD, Giuseppe Saglio, Zhi-Xiang Shen, MD
Journal: Blood
Blood (2013) 122 (21): 1497.
https://doi.org/10.1182/blood.V122.21.1497.1497
Published: 2013
Journal Articles

SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment

Bo Huang, Zhang Lei, Gui-Mei Zhang, Dong Li, Chuanwang Song, Bo Li, Yanyan Liu, Ye Yuan, Jay Unkeless, Huabao Xiong, Zuo-Hua Feng
Journal: Blood
Blood (2008) 112 (4): 1269–1279.
https://doi.org/10.1182/blood-2008-03-147033
Published: 2008
Includes: Supplemental data